To the Editor: The report by Wenzel et al. (June 27 issue)(1) about the use of dupilumab in patients with persistent asthma and elevated eosinophil levels would be more complete if analyses of subjective efficacy and safety were also presented for the participants with no injection-site reactions. Although the study was masked with respect to treatment and placebo, the occurrence of local reactions might bias participants and investigators.To the Editor: Obesity may have a confounding effect on the results of the study reported by Wenzel et al. Clinically, there is an obesity-related noneosinophilic asthma phenotype that is observed more ...